RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV | BMC Cancer | Full Text

RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV | BMC Cancer | Full Text

RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV

Despite obvious advances over the last decades, locally advanced adenocarcinomas of the gastroesophageal junction (GEJ) still carry a dismal prognosis with overall 5-year survival rates of less than 50% even w...

Authors:Sylvie Lorenzen, Alexander Biederstädt, Ulrich Ronellenfitsch, Christoph Reißfelder, Stefan Mönig, Frederik Wenz, Claudia Pauligk, Martin Walker, Salah-Eddin Al-Batran, Bernhard Haller and Ralf-Dieter Hofheinz

Citation:BMC Cancer 2020 20:886

Content type:Study protocol

 

Published on: 15 September 2020

• ViewFull Text
 
• ViewPDF